Serum Lipoprotein-a as a Marker of Severity of Coronary Artery Disease in Aortic Valve Sclerosis Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-10-01

Study Completion Date

2025-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This work aimed to evaluate the association of serum level of Lp(a) with the severity of coronary artery disease (CAD) in aortic valve sclerosis (AVS) patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Lipoprotein (a) on Arterial Stiffness, Endothelial Function and Myocardial Deformation

NCT07324902

Lipoprotein Disorder Arterial Stiffness Endothelial Dysfunction

RECRUITING

Comparative Study of Antegrade Versus Retrograde Cerebral Perfusion in Acute Type A Aortic Dissection: A Prospective Study

NCT06870513

Acute Type A Aortic Dissection

COMPLETED NA

Aortic Calcification - is it a Marker for Carotid Artery Stenosis?

NCT01458860

Carotid Artery Stenosis Aortic Calcification

UNKNOWN

Serum and Cellular Biomarkers for Aortic Valve Stenosis

NCT04312139

Calcific Aortic Valve Disease Aortic Valve Stenosis Aortic Valve, Calcification of

UNKNOWN

Impact of Aortic Geometry on Vascular Remodeling After Stent Implantation in Coarctation of the Aorta

NCT07131111

Aortic Geometry Vascular Remodeling Coarctation of Aorta +6 more

NOT_YET_RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Aortic valve sclerosis (AVS) has a prevalence of 2% to 7% in the population above 65 years of age. In industrialized countries, aortic valve sclerosis is most frequently caused by progressive calcification and degeneration of the aortic cusps.

Coronary artery disease (CAD) is the most significant single cause of death in the world. In developed countries, more than 25% of all deaths in persons older than 35 years are due to CAD. More than half of acute myocardial infarctions occur without previous history or symptoms of CAD.

In recent years, there has been a special emphasis on lipoprotein(a) (Lp(a)), a significant, causal, and nonmodifiable predictor of valvular outcomes and CAD in the general population

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Serum Lipoprotein(A) Severity Coronary Artery Disease Aortic Valve Sclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Study group

Patients with chest pain and/or dyspnea were diagnosed provisionally as having coronary artery disease.

Serum Lipoprotein-a level

Intervention Type OTHER

A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10 minutes at 2-8 °C, after which the serum was divided into aliquots and stored at -20 ° C.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Serum Lipoprotein-a level

A venous blood sample was taken from each patient a month or so after discharge to check their Lp (a) levels. The samples were centrifuged for 10 minutes at 2-8 °C, after which the serum was divided into aliquots and stored at -20 ° C.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years.
* Both sexes.
* Patients with chest pain and/or dyspnea were diagnosed provisionally as having coronary artery disease.

Exclusion Criteria

* Aortic stenosis.
* Aortic prosthesis.
* Untreated hypothyroidism.
* Severe chronic kidney failure.
* Administration of anti-inflammatory or immunosuppressive drugs.
* Pregnancy.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No